BACKGROUND: Cancer prevention is essential after transplantation (Tx). The use of HE4 and Risk of Ovarian Malignancy Algorithm (ROMA) is recommended as a tool for selective ovarian cancer screening; however, creatinine is a known confounder. This study assessed the reliability of HE4, CA125, and ROMA after Tx. METHODS: We matched a total of 202 women without gynecological malignancies and 236 men by age and serum creatinine. Each pair consisted of a patient after Tx (kidney, liver, heart, and pancreas) and a diseased but non-Tx consecutive patient. Serum HE4, CA125 (Roche Cobas 6000), and creatinine (enzymatic, Abbott Architect) were measured in all patients. RESULTS: Creatinine correlated with HE4 (women: r = .864, P < .0001; men: r = .848, P < .0001). Age correlated slightly with HE4 in women (r = .250, P < .005) and men (r = .240, P < .0005). HE4 in women after Tx (median of 84.8 pmol/L) was significantly higher than non-Tx women (53.7 pmol/L, P < .0001) in the reference range of serum creatinine. Neither HE4 nor CA125 correlated with tacrolimus concentration, but anemia, hyperparathyroidism, kidney, liver, and lung diseases were possible confounders for HE4 after transplantation (P < .05). CONCLUSION: Human epididymis protein 4 (HE4) was significantly increased in women after solid organ transplantation compared to levels without transplants matched by age and serum creatinine. HE4 results may be misleading in these patients.

3rd Faculty of Medicine Charles University Prague Czech Republic

Department of Biostatistics Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Laboratory Methods Institute for Clinical and Experimental Medicine Prague Czech Republic

Gynecology Outpatient Department Institute for Clinical and Experimental Medicine Prague Czech Republic

Zobrazit více v PubMed

Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402‐408. PubMed

Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40‐46. PubMed PMC

Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011;118:280‐288. PubMed PMC

Chudecka‐Głaz AM. ROMA, an algorithm for ovarian cancer. Clin Chim Acta. 2015;440:143‐151. PubMed

Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol. 2013;66:273‐281. PubMed

Lin J, Qin J, Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta‐analysis. Eur J Obstet Gynecol Reprod Biol. 2013;167:81‐85. PubMed

Zhang Q, Wang CR, Yu JP, Ma Q, Xu WW. The establishment of an HE4‐CLIA method and the combined analysis of HE4 and CA125 in ovarian cancer. J Clin Lab Anal. 2016;30:709‐718. PubMed PMC

Granato T, Porpora MG, Longo F, Angeloni A, Manganaro L. Anastasi E HE4 in the differential diagnosis of ovarian masses. Clin Chim Acta. 2015;446:147‐155. PubMed

Nagy B Jr, Krasznai ZT, Balla H, et al. Elevated human epididymis protein 4 concentrations in chronic kidney disease. Ann Clin Biochem. 2012;49:377‐380. PubMed

Kappelmayer J, Antal‐Szalmás P, Nagy B Jr. Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders. Clin Chim Acta. 2015;438:35‐42. PubMed

Gizzo S, Ancona E, Saccardi C, D'Antona D, Nardelli GB, Plebani M. Could kidney glomerular filtration impairment represent the “Achilles heel” of HE4 serum marker? A possible further implication. Clin Chem Lab Med. 2014;52:e45‐e46. PubMed

Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem. 2011;57:1534‐1544. PubMed

Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306:1891‐1901. PubMed PMC

Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4:905‐913. PubMed

Molmenti EP, Molmenti H, Weinstein J, et al. Syndromic incidence of ovarian carcinoma after liver transplantation, with special reference to anteceding breast cancer. Dig Dis Sci. 2003;48:187‐189. PubMed

Krynitz B, Edgren G, Lindelöf B, et al. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008–a Swedish population‐based study. Int J Cancer. 2013;132:1429‐1438. PubMed

Zhou J, Hu Z, Zhang Q, et al. Spectrum of de novo cancers and predictors in liver transplantation: analysis of the scientific registry of transplant recipients database. PLoS One. 2016;11:e0155179. PubMed PMC

Buell JF, Woodle ES. Syndromic incidence of ovarian cancer after liver transplantation: is breast cancer an antecedent risk? Liver Transpl. 2004;10:156‐157. PubMed

Bolstad N, Øijordsbakken M, Nustad K, Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol. 2012;33:141‐148. PubMed PMC

Shin JJ, Lee YJ, Kim R, da Lee Y, Won KH, Jee BC. Analysis of falsely elevated risk of ovarian malignancy algorithm in women with ovarian endometrioma. Obstet Gynecol Sci. 2016;59:295‐302. PubMed PMC

Anastasi E, Granato T, Marchei GG, et al. Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women. Tumour Biol. 2010;31:411‐415. PubMed

Hallamaa M, Suvitie P, Huhtinen K, Matomäki J, Poutanen M, Perheentupa A. Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women. Gynecol Oncol. 2012;125:667‐672. PubMed

Karlsen NS, Karlsen MA, Høgdall CK, Høgdall EV. HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review. Cancer Epidemiol Biomarkers Prev. 2014;23:2285‐2295. PubMed

Lu J, Zheng Z, Zhang Q, et al. Measurement of HE4 and CA125 and establishment of reference intervals for the ROMA index in the sera of pregnant women. J Clin Lab Anal. 2017;e22368 10.1002/jcla.22368. PubMed DOI PMC

Valentin L, Jurkovic D, Van Calster B, et al. Adding a single CA 125 measurement to ultrasound imaging performed by an experienced examiner does not improve preoperative discrimination between benign and malignant adnexal masses. Ultrasound Obstet Gynecol. 2009;34:345‐354. PubMed

Van Calster B, Timmerman D, Bourne T, et al. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA‐125. J Natl Cancer Inst. 2007;99:1706‐1714. PubMed

Van Gorp T, Veldman J, Van Calster B, et al. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. Eur J Cancer. 2012;48:1649‐1656. PubMed

Qu W, Li J, Duan P, et al. Physiopathological factors affecting the diagnostic value of serum HE4‐test for gynecologic malignancies. Expert Rev Mol Diagn. 2016;16:1271‐1282. PubMed

Capriglione S, Plotti F, Miranda A, et al. Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4. Expert Rev Anticancer Ther. 2017;17:9‐18. PubMed